Osta Biotechnologies Inc.
TSX VENTURE : OBI

Osta Biotechnologies Inc.

October 15, 2007 07:00 ET

Media Advisory-REMINDER: Osta Biotechnologies and the Segal Cancer Centre at the Jewish General Hospital to Announce Results on a New Experimental Cancer Drug

MONTREAL, QUEBEC--(Marketwire - Oct. 15, 2007) - Osta Biotechnologies (TSX VENTURE:OBI), a Montreal-based biotechnology company involved in the discovery and development of novel diagnostics and therapeutics and the Jewish General Hospital's Segal Cancer Centre, to announce results of Osta's lead anti-cancer drug on Monday, October 15, 2007.

Media representatives are invited to a news conference for the presentation of these results. The conference will take place on Monday, October 15, 2007, at 10 a.m. at the Jewish General Hospital, 3999 Cote Sainte-Catherine, Montreal.



NOTE: A news release will be transmitted on Marketwire on October 15th at
10 a.m.

What? Announcement of results on a new experimental cancer drug

Who? Dr. Ajay Gupta, Chairman and Chief Executive Officer of
Osta Biotechnologies Inc.

Dr. Hyman M. Schipper, Director of Neurotranslational Centre at
the Jewish General Hospital

Dr. Gerald Batist, Director of the Segal Cancer Centre at the
Jewish General Hospital

Dr. Michael Munzar, Vice President, Medical and Regulatory
Affairs, Osta Biotechnologies Inc.

When? October 15, 2007, at 10 a.m.

Where? Jewish General Hospital
Lady Davis Institute
Bloomfield Lecture Hall
3999 Cote Sainte-Catherine
Montreal, QC H3T 1E2

Contact Information

  • Jean-Pierre Trudel & Associates
    Jean-Pierre Trudel
    514-347-6111
    or
    Jewish General Hospital
    Reena Kudhail
    Public Affairs and Communications
    514-340-8222, ext. 4120